250 related articles for article (PubMed ID: 15917863)
1. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice.
Carmona MC; Lefebvre P; Lefebvre B; Galinier A; Benani A; Jeanson Y; Louche K; Flajollet S; Ktorza A; Dacquet C; Pénicaud L; Casteilla L;
Int J Obes (Lond); 2009 Feb; 33(2):204-11. PubMed ID: 19125161
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Fernandes-Santos C; Evangelista Carneiro R; de Souza Mendonca L; Barbosa Aguila M; Mandarim-de-Lacerda CA
Pancreas; 2009 Apr; 38(3):e80-6. PubMed ID: 19214135
[TBL] [Abstract][Full Text] [Related]
4. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
6. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
7. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
[TBL] [Abstract][Full Text] [Related]
10. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
11. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
12. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone.
Nadeau KJ; Ehlers LB; Aguirre LE; Reusch JE; Draznin B
Diabetes Obes Metab; 2007 Sep; 9(5):714-23. PubMed ID: 17697064
[TBL] [Abstract][Full Text] [Related]
13. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
[TBL] [Abstract][Full Text] [Related]
14. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
16. Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.
Ji H; Outterbridge LV; Friedman MI
Metabolism; 2005 Apr; 54(4):421-9. PubMed ID: 15798946
[TBL] [Abstract][Full Text] [Related]
17. Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.
Wagner JA; Larson PJ; Weiss S; Miller JL; Doebber TW; Wu MS; Moller DE; Gottesdiener KM
J Clin Pharmacol; 2005 May; 45(5):504-13. PubMed ID: 15831773
[TBL] [Abstract][Full Text] [Related]
18. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
Ide T; Tsunoda M; Mochizuki T; Murakami K
Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
Ferreira AV; Parreira GG; Porto LC; Mario EG; Delpuerto HL; Martins AS; Botion LM
Life Sci; 2008 Apr; 82(15-16):876-83. PubMed ID: 18374364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
